ClinicalTrials.gg
CompletedNCT07160400Updated Sep 11, 2026

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

A Phase 1 interventional study of Placebo and IBI3032 tablets in Part A: Healthy Part B: Overweight or Obesity, sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center). Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center) (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Obesity by Innovent Biologics, Inc. — 5 open to participants now, 9 under way, 4 of them phase 3. Obesity · Innovent Biologics, Inc..

Enrollment
12th of 16
80 · median 135
Started
2025
with 5 others
Phase 1
6 of 16
2 open now
Registered
11th of 16
by date

Among the 16 studies in Obesity by Innovent Biologics, Inc., this one is the 12th largest by enrollment, is one of 6 that started in 2025, is one of 6 in phase 1, and was the 11th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 16 studies in Obesity by Innovent Biologics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Obesity by Innovent Biologics, Inc., or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.

03

Conditions studied

  • Part A: Healthy Part B: Overweight or Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18-65 years (inclusive) at the time of .
  2. Participants must understand the procedures and methods of this study, be willing to complete the study in strict accordance with the clinical study protocol, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. The investigator suspects that the participant may be allergic to any component of the study drug or GLP-1 receptor agonists, or have used GLP-1 receptor agonists within 3 months prior to screening.
  2. History of diabetes, or ≥ 6.5% and fasting blood glucose \< 3.9 mmol/L or ≥ 7.0 mmol/Lat screening.
  3. Presence of any other abnormalities in vital signs and laboratory tests that are as judged by the investigator at screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Single dose of IBI3032 administered orally.

    Part A

    Drug: IBI3032 tablets

  • Placebo comparator
    Single dose of placebo administered orally.

    Part A

    Drug: Placebo

  • Experimental
    Multiple doses of IBI3032 administered orally.

    Part B

    Drug: IBI3032 tablets

  • Placebo comparator
    Multiple doses of placebo administered orally.

    Part B

    Drug: Placebo

Interventions

  • DrugPlacebo

    Single dose placebo IBI3032 administered orally

  • Single dose of IBI3032 administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants with adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

    Time frame: Part A: Baseline up to Day 15

  2. Number of Participants with adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

    Time frame: Part B: Baseline up to Day 43

  3. Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Part A: Baseline up to Day 15

  4. Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Part B: Baseline up to Day 43

  5. Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

    A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Part A: Baseline up to Day 15

  6. Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

    A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Part B: Baseline up to Day 43

Secondary outcomes

  1. Under the Serum Concentration-time Curve (AUC) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Part A: Predose up to 168 hours postdose

  2. Under the Serum Concentration-time Curve (AUC) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.

    Time frame: Part B: Predose up to 168 hours postdose

  3. maximum concentration (Cmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Part A: Predose up to 168 hours postdose

  4. maximum concentration (Cmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.

    Time frame: Part B: Predose up to 168 hours postdose

  5. time to maximum concentration (Tmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Part A: Predose up to 168 hours postdose

  6. time to maximum concentration (Tmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.

    Time frame: Part B: Predose up to 168 hours postdose

  7. clearance (CL) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Part A: Predose up to 168 hours postdose

  8. clearance (CL) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.

    Time frame: Part B: Predose up to 168 hours postdose

  9. apparent volume of distribution (V) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Part A: Predose up to 168 hours postdose

  10. apparent volume of distribution (V) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.

    Time frame: Part B: Predose up to 168 hours postdose

  11. elimination half-life (T1/2) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Part A: Predose up to 168 hours postdose

  12. elimination half-life (T1/2) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.

    Time frame: Part B: Predose up to 168 hours postdose

07

Study locations

1 site
  • Zhongshan Hospital affiliated to Fudan University
    Shanghai, Shanghai Municipality 200030, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Aug 2026, 11 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Sep 8, 2025
StartActual
Sep 4, 2025
Primary completionActual
Aug 6, 2026
CompletionActual
Aug 10, 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07160400
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 4, 2025
Primary completion
Aug 6, 2026
Completion
Aug 10, 2026
Last update
Sep 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3032

Start the discussion